Welcome.AI
    Skip to content

    Cleerly

    Visit Website

    Company Facts

    About Cleerly

    Cleerly announced the primary results of the PARAMOUNT trial, the first randomized study to evaluate AI-enabled quantitative coronary CT (AI-QCT) in guiding care for patients with suspected coronary artery disease (CAD).

    Where AI Leaders Stay Informed

    The latest AI intelligence, case studies, and research — delivered to your inbox every week.

    Free to read. Unsubscribe anytime.

    Is this your company?

    Claim this profile to manage information and unlock premium features.